Scott Dunseth Myers
CIK 1356256 · Chief Executive Officer · last filed 2026-06-18
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$6.89M
Companies
10
Total Filings
54
Lifetime Open-Market Net
$555.0K
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ZNTL | Director | 395,895 | $4.62 | $1.83M | $29.4K | 4 | 2026-06-18 |
| DYNAVAX TECHNOLOGIES CORP (DVAX) Delisted | Director | 0 | $15.50 | $0 | $41.1K | 7 | 2026-02-10 |
| Harpoon Therapeutics, Inc. (HARP) Delisted | Director | 0 | $23.01 | $0 | $0 | 13 | 2024-03-11 |
| RNAC | Director | — | $7.65 | — | $0 | 1 | 2023-11-15 |
| VRDN | Chief Executive Officer | 259,500 | $19.51 | $5.06M | $261.8K | 3 | 2023-04-12 |
| Cartesian Therapeutics, Inc. (SELB) Delisted | Director | 80,845 | $0.88 | $71.2K | $0 | 7 | 2023-01-04 |
| Trillium Therapeutics Inc. (TRIL) Delisted | Director | — | $19.86 | — | $0 | 1 | 2021-05-05 |
| AMAG PHARMACEUTICALS, INC. (AMAG) Delisted | President & CEO | — | — | — | $0 | 2 | 2020-11-17 |
| Cascadian Therapeutics, Inc. (CASC) Delisted | President and CEO | 56,787 | — | — | $222.7K | 12 | 2018-02-02 |
| Cascadian Therapeutics, Inc. (ONTY) Delisted | President and CEO | — | — | — | $0 | 1 | 2016-04-06 |
Recent Filings · Page 2 of 6
54 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2023-11-28 | Harpoon Therapeutics, Inc. (HARP) Delisted | Grant (A) | +5,000 | $0 | EDGAR |
| 2023-11-16 | VRDN | Notice (144) | −35,368 | -$535.1K | EDGAR |
| 2023-11-15 | RNAC | Disp (D) | — | $0 | EDGAR |
| 2023-10-02 | Harpoon Therapeutics, Inc. (HARP) Delisted | Grant (A) | +5,797 | $0 | EDGAR |
| 2023-07-06 | Harpoon Therapeutics, Inc. (HARP) Delisted | Grant (A) | +35,634 | $0 | EDGAR |
| 2023-06-23 | Harpoon Therapeutics, Inc. (HARP) Delisted | Grant (A) | — | $0 | EDGAR |
| 2023-05-31 | DYNAVAX TECHNOLOGIES CORP (DVAX) Delisted | Grant (A) | +5,357 | $0 | EDGAR |
| 2023-04-12 | VRDN | Buy (P) | +4,000 | $101.5K | EDGAR |
| 2023-04-04 | Harpoon Therapeutics, Inc. (HARP) Delisted | Grant (A) | +34,925 | $0 | EDGAR |
| 2023-03-13 | VRDN | Buy (P) | +5,500 | $160.3K | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.